Medication info
Orotenion Tablet 10/40 mg (Amlodipine Besilate, Olmesartan Medoxomil)

Orotenion Tablet 10/40 mg (Amlodipine Besilate, Olmesartan Medoxomil)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Korea Pharmaceutical Co., Ltd.
Appearance
Brownish-red round film-coated tablets
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201505941 · Approved 2015.08.25 · Insurance code 642802770

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, with or without food. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose of the individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy with either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. · Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. · Patients with reduced intravascular volume: In patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. · Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) · Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Korea Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Used in patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with amlodipine or olmesartan medoxomil. The combination therapy of these two drugs can enhance blood pressure control effects, helping to lower blood pressure more effectively and improve the risk of cardiovascular complications. By managing blood pressure stably, it improves the overall health status of patients.

How to take

Adult dose

Administer 1 tablet once daily with water, with or without food. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose of the individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy with either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. · Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. · Patients with reduced intravascular volume: In patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. · Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) · Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be taken if there is an allergy to any of its components, or if one is pregnant or breastfeeding, or if there are serious liver diseases or certain heart and kidney diseases. Patients with hypotension due to a lack of fluid or salt should be cautious when starting this medication, as blood pressure can drop sharply; appropriate action should be taken immediately if symptoms occur. Caution should be exercised when administering this medication to patients with severe heart valve disease since there is a risk of rapid blood pressure drop due to vasodilation. Patients with heart diseases, such as occlusive coronary artery disease or congestive heart failure, may experience worsening of symptoms when taking this medication, necessitating careful use. Patients with impaired kidney function may experience worsening of kidney function when taking this medication and should have regular blood tests and kidney function tests. Patients with reduced liver function may also experience delayed metabolism and excretion of this medication, so caution is required during administration. Side effects such as dizziness, headache, hypotension, indigestion, and edema may occur during treatment; if severe symptoms arise, a doctor should be consulted. Pregnant women or those planning to become pregnant should use other antihypertensive medications with confirmed safety instead of this medication, as it poses a risk to the fetus during pregnancy; they must consult with a doctor before taking this medication. Breastfeeding women should consult a doctor about stopping breastfeeding or medication as this drug can pass into breast milk and affect the infant. Children under 18 years old should avoid taking this medication since its safety and efficacy have not been established. Elderly patients (over 65 years) may react more sensitively to this medication; therefore, starting with a lower dose and closely monitoring their condition is advisable. In cases of overdose, blood pressure may drop significantly, and heart rhythms may become irregular; immediate emergency treatment is required if such symptoms occur. This medication should be stored away from moisture, heat, and direct sunlight, in a place out of reach of children, and it is advisable not to transfer it to another container.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • altered perception
  • perception decrease
  • syncope
Show 84 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholecystitis
  • breast neoplasm in women
  • exacerbation of cerebral infarction
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • side pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • double vision
  • insomnia
  • asthenia
  • vascular edema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • hyperkalemia
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is advised to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will safely retain the drug's efficacy.

Appearance and packaging

Appearance

Brownish-red round film-coated tablets

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.